$10.65
0.090.85%
At close: -
$10.20
-0.45-4.23%
After Hours: 6:21 PM EDT
Comments
Loading...
Adaptive Biotechnologies Analyst Ratings and Price Targets | NASDAQ:ADPT | Benzinga
Adaptive Biotechnologies Corp has a consensus price target of $10.13 based on the ratings of 8 analysts. The high is $15 issued by Craig-Hallum on June 18, 2025. The low is $6 issued by JP Morgan on August 2, 2024. The 3 most-recent analyst ratings were released by Craig-Hallum, Piper Sandler, and Morgan Stanley on June 18, 2025, May 6, 2025, and May 5, 2025, respectively. With an average price target of $12.33 between Craig-Hallum, Piper Sandler, and Morgan Stanley, there's an implied 20.92% upside for Adaptive Biotechnologies Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Craig-Hallum
Piper Sandler
Morgan Stanley
Goldman Sachs
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Adaptive Biotechnologies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/18/2025 | Buy Now | 47.06% | Craig-Hallum | John Wilkin39% | → $15 | Initiates | → Buy | Get Alert |
| 05/06/2025 | Buy Now | 27.45% | Piper Sandler | David Westenberg61% | $11 → $13 | Maintains | Overweight | Get Alert |
| 05/05/2025 | Buy Now | -11.76% | Morgan Stanley | Tejas Savant51% | $7 → $9 | Maintains | Equal-Weight | Get Alert |
| 05/02/2025 | Buy Now | -1.96% | Goldman Sachs | Salveen Richter51% | $9 → $10 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | -11.76% | Goldman Sachs | Salveen Richter51% | $8 → $9 | Upgrade | Neutral → Buy | Get Alert |
| 02/20/2025 | Buy Now | 7.84% | Piper Sandler | David Westenberg61% | $7 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 02/13/2025 | Buy Now | 17.65% | Scotiabank | Sung Ji Nam46% | $10 → $12 | Maintains | Sector Outperform | Get Alert |
| 01/28/2025 | Buy Now | -26.47% | Goldman Sachs | Salveen Richter51% | $5.5 → $7.5 | Maintains | Neutral | Get Alert |
| 12/18/2024 | Buy Now | -11.76% | BTIG | Mark Massaro71% | $8 → $9 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | -31.37% | Piper Sandler | David Westenberg61% | $6 → $7 | Maintains | Overweight | Get Alert |
| 10/02/2024 | Buy Now | -21.57% | BTIG | Mark Massaro71% | $7 → $8 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | -41.18% | JP Morgan | Rachel Vatnsdal65% | $5 → $6 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | -50.98% | JP Morgan | Rachel Vatnsdal65% | $8 → $5 | Maintains | Overweight | Get Alert |
| 04/04/2024 | Buy Now | -50.98% | BTIG | Mark Massaro71% | $6 → $5 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -50.98% | Goldman Sachs | Salveen Richter51% | $11 → $5 | Maintains | Neutral | Get Alert |
| 02/15/2024 | Buy Now | -21.57% | JP Morgan | Rachel Vatnsdal65% | $11 → $8 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | -41.18% | Piper Sandler | David Westenberg61% | $13 → $6 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 7.84% | JP Morgan | Rachel Vatnsdal65% | $12 → $11 | Maintains | Overweight | Get Alert |
| 10/24/2023 | Buy Now | -1.96% | Morgan Stanley | Tejas Savant51% | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 27.45% | Piper Sandler | David Westenberg61% | $14 → $13 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 37.25% | Piper Sandler | David Westenberg61% | $15 → $14 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 27.45% | Morgan Stanley | Tejas Savant51% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 37.25% | Morgan Stanley | Tejas Savant51% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 02/16/2023 | Buy Now | 47.06% | Morgan Stanley | Tejas Savant51% | $16 → $15 | Maintains | Equal-Weight | Get Alert |
| 02/15/2023 | Buy Now | -31.37% | Credit Suisse | Dan Leonard55% | → $7 | Reiterates | → Underperform | Get Alert |
| 01/05/2023 | Buy Now | 47.06% | Scotiabank | Sung Ji Nam46% | → $15 | Initiates | → Sector Outperform | Get Alert |
| 12/21/2022 | Buy Now | 37.25% | Piper Sandler | David Westenberg61% | $7.5 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2022 | Buy Now | 56.86% | Morgan Stanley | Tejas Savant51% | $17 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/26/2022 | Buy Now | -26.47% | Piper Sandler | David Westenberg61% | $12 → $7.5 | Maintains | Neutral | Get Alert |
| 08/25/2022 | Buy Now | -21.57% | Credit Suisse | Dan Leonard55% | → $8 | Initiates | → Underperform | Get Alert |
| 08/17/2022 | Buy Now | 17.65% | Piper Sandler | David Westenberg61% | $7.5 → $12 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Adaptive Biotechnologies (ADPT) stock?
The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Craig-Hallum on June 18, 2025. The analyst firm set a price target for $15.00 expecting ADPT to rise to within 12 months (a possible 47.06% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?
The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Craig-Hallum, and Adaptive Biotechnologies initiated their buy rating.
When was the last upgrade for Adaptive Biotechnologies (ADPT)?
The last upgrade for Adaptive Biotechnologies Corp happened on March 21, 2025 when Goldman Sachs raised their price target to $9. Goldman Sachs previously had a neutral for Adaptive Biotechnologies Corp.
When was the last downgrade for Adaptive Biotechnologies (ADPT)?
There is no last downgrade for Adaptive Biotechnologies.
When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on June 18, 2025 so you should expect the next rating to be made available sometime around June 18, 2026.
Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a initiated with a price target of $0.00 to $15.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $10.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
